Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) posted its quarterly earnings results on Tuesday. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.91, Briefing.com reports. The company had revenue of $40.56 million during the quarter, compared to the consensus estimate of $35.00 million. During the same quarter in the prior year, the business earned ($1.07) earnings per share.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $12.31 on Wednesday. The company has a market capitalization of $874.13 million, a P/E ratio of -2.71 and a beta of 1.82. Zentalis Pharmaceuticals has a 52 week low of $9.56 and a 52 week high of $31.46. The company’s 50 day moving average price is $13.76 and its two-hundred day moving average price is $13.43.

Wall Street Analysts Forecast Growth

ZNTL has been the topic of a number of recent analyst reports. Wedbush raised their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a report on Wednesday, February 28th. HC Wainwright restated a “buy” rating and set a $46.00 price objective on shares of Zentalis Pharmaceuticals in a report on Wednesday, February 28th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $38.57.

Insider Transactions at Zentalis Pharmaceuticals

In related news, CFO Melissa B. Epperly sold 2,573 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the transaction, the chief financial officer now directly owns 451,449 shares of the company’s stock, valued at approximately $5,164,576.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.10% of the stock is owned by insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.